Otsuka Pharmaceuticals submits to FDA application for Torbaptan, a drug for the treatment of a genetic disease (autosomal dominant polycystic kidney (ADPKD))

This is considered to be the first drug for the treatment of a genetic disease.

Otsuka Pharmaceuticals press release, April 12, 2013

Otsuka Pharmaceuticals submits to FDA application for Torbaptan, a drug for the treatment of a genetic disease (autosomal dominant polycystic kidney (ADPKD))
Scroll to top